Sofinnova Partners: Investment Portfolio & Startup News
Sofinnova Partners
To add a bio or update investment portfolio click update information.
Investment Portfolio


T-Therapeutics closes a £100m Series B led by Advent Life Sciences and British Business Bank to take its cancer and autoimmune treatments into clinical trials
T-Therapeutics is a biotechnology company developing T cell engager treatments based on human T cell receptors. Its drug programmes target cancer and autoimmune diseases.


Alethio Therapeutics secures a £67m Series A round led by Sofinnova Partners and RA Capital to develop targeted blood cancer therapies
Alethio Therapeutics is developing targeted therapies for myeloproliferative neoplasms (MPNs), a group of chronic, incurable blood cancers. Its lead programme, ATX-011, is a monoclonal antibody that targets the G6B protein and is designed to treat essential thrombocythaemia.


Mironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Mironid is a Glasgow-based biopharmaceutical company developing small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease, a life-threatening hereditary kidney disease with limited treatment options. Its first-in-class LoAc drug candidates target the abnormally high kidney cAMP levels that drive the uncontrolled growth of fluid-filled cysts.


Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye
Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.


T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.


Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.


Latent Labs raises £40m Series A led by Radical Ventures and Sofinnova Partners to advance AI protein design
Latent Labs develops AI foundation models for generative protein design, enabling biotech and pharmaceutical teams to computationally design new antibodies, enzymes and therapeutics more efficiently.
- 4(12 months)
- sofinnovapartners.com
More venture news
- 17 Nov 2026

Model MLModel ML secures a £190m Series B led by General Atlantic and QED Investors to expand its AI operating system for financial services
Series BFintech - 16 Nov 2026

SubdialSubdial secures a £15m Series B led by Gresham House Ventures to buy and sell pre-owned watches
Series BConsumer - 12 Nov 2026

GriffinGriffin closes a £15m Series B led by Octagon Partners to add cards and stablecoin payments to its banking platform
Series BFintech